Skin is one of the most frequently involved organs in human immunodeficiency virus (HIV) infection, and mucocutaneous manifestations may be one of the earliest markers of AIDS. The prevalence of cutaneous abnormalities in HIV approaches nearly 90%. Mucocutaneous manifestations may also act as a prognostic marker of HIV infection. Children are increasingly being affected by HIV infection and it is important to realize the presence of the infection early in the disease process as their immune status is not mature enough to handle the stress of various infections. Skin manifestations can serve as early markers and prognostic indicators of HIV infection. This review highlights the epidemiology, transmission, pathogenesis, and the mucocutaneous manifestations of HIV infection in children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0378-6323.69041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A global review of national guidelines of post-exposure prophylaxis for the prevention of HIV.
J Int AIDS Soc
January 2025
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Introduction: The World Health Organization (WHO) recommends the use of antiretroviral drugs as post-exposure prophylaxis (PEP) for preventing HIV acquisition for occupational and non-occupational exposures. To inform the development of global WHO recommendations on PEP, we reviewed national guidelines of PEP for their recommendations.
Methods: Policies addressing PEP from 38 WHO HIV priority countries were obtained by searching governmental and non-governmental websites and consulting country and regional experts; these countries were selected based on HIV burden, new HIV acquisitions and the number of HIV-associated deaths.
COVID-19 impact on HIV PrEP uptake and retention at selected health facilities in Eswatini.
Afr J Prim Health Care Fam Med
December 2024
School of Public Health, Faculty of Community and Health Sciences, University of the Western Cape, Cape Town.
Background: Oral pre-exposure prophylaxis (PrEP) uses antiretroviral medication to reduce HIV risk in HIV-negative individuals. Despite its effectiveness, global uptake faces policy and accessibility challenges. In Eswatini, PrEP introduction in 2017 showed promise despite stigma and COVID-19 disruptions.
View Article and Find Full Text PDFFactors associated with HIV testing among young women in Tanzania: Insights from the 2022 Tanzanian Demographic and Health Survey using Anderson's Behavioral Model.
Front Public Health
January 2025
School of Public Health, College of Health Sciences and Medicine, Dilla University, Dilla, Ethiopia.
Background: HIV continues to be a significant global health issue, particularly affecting sub-Saharan Africa, including Tanzania. Knowing one's HIV status is a crucial first step in combating HIV/AIDS and achieving the targets set for the Sustainable Development Goals (SDGs) by 2030. However, despite ongoing efforts, HIV testing coverage remains low in developing countries, including Tanzania, where testing among young people poses particular challenges.
View Article and Find Full Text PDFAssessment of the knowledge, attitudes, and risk perceptions of pharmacy students regarding HIV/AIDS.
Front Public Health
January 2025
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Background: We recognize AIDS and HIV as serious public health concerns. One of the primary roles of pharmacists is to counsel patients, which is critical in improving patient care outcomes. Therefore, having an adequate understanding of HIV among undergraduates helps them at their practice sites.
View Article and Find Full Text PDFEffect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration.
Clin Pharmacol Drug Dev
January 2025
Gilead Sciences, Inc., Foster City, CA, USA.
Lenacapavir is a potent, long-acting HIV-1 capsid inhibitor used in combination with other antiretrovirals to treat HIV-1 infection. The pharmacokinetics of orally administered drugs may be affected by food intake or coadministration of acid-reducing agents (ARA). Two Phase 1 studies were conducted on healthy participants to evaluate the effect of food and the impact of the histamine H-receptor antagonist famotidine in parallel cohorts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!